AiViva Biopharma Archives | Be Korea-savvy

Home / Posts tagged AiViva Biopharma

AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema

Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (Korea Bizwire) – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 trial with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME). “We have achieved a major [...]

AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer

Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (Korea Bizwire) – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced completion of their first trial administering AIV001 (axitinib) to patients diagnosed with basal cell carcinoma (BCC) tumors. AIV001 is AiViva’s novel intradermally administered product designed for local, prolonged treatment effect [...]

AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors

COSTA MESA, Calif., Sept. 18, 2023 (Korea Bizwire) – AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Dr. Lester J. Kaplan, PhD to its board of directors. Dr. Kaplan served as the Executive Vice President and President, Research & Development and Global [...]

AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema

Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., May 22 (Korea Bizwire) — AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME).  “We are very excited to [...]